Sentinel lymph node biopsy for breast cancer: A suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used

Journal of Clinical Oncology

Volumn 18, Issue 13, 2000, Pages 2560-2566

  McMasters, Kelly M kelly ^a   Tuttle, Todd M ^a   Carlson, David J ^a   Brown, C Matthew ^a   Noyes, R Dirk ^a   Glaser, Rebecca L ^a   Vennekotter, Donald J ^a   Turk, Peter S ^a   Tate, Peter S ^a   Sardi, Armando ^a   Cerrito, Patricia B ^a   Edwards, Michael J ^a  

^a LDS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RELIABILITY; STAINING;

EID: 0033917285     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.13.2560     Document Type: Article

References (32)

1. Petrek JA, Heelan MC: Incidence of breast carcinoma-related lymphedema. Cancer 83:2776-2781, 1997
2. Velanovich V, Szymanski W: Quality of life of breast cancer patients with lymphedema. Am J Surg 177:184-188, 1999
3. Hack TF, Cohen L, Katz J, et al: Physical and psychological morbidity after axillary lymph node dissection for breast cancer. J Clin Oncol 17:143-149, 1999
4. Ollila DW,. Brennan MB, Giuliano AE: The role of intraoperative lymphatic mapping and sentinel lymphadenectomy in the management of patients with breast cancer. Adv Surg 32:349-364, 1999
5. Veronesi U, Paganelli G, Viale G, et al: Sentinel lymph node biopsy and axillary dissection in breast cancer: Results in a large series. J Natl Cancer Inst 91:368-373, 1999
6. Cody HS III: Sentinel lymph node mapping in breast cancer. Oncology 13:25-34, 1999
7. Cox CE, Haddad F, Bass S, et al: Lymphatic mapping in the treatment of breast cancer. Oncology 12:1283-1292, 1998
8. Krag D, Weaver D, Ashikaga T, et al: The sentinel node in breast cancer: A multicenter validation study. N Engl J Med 339:941-946, 1998
9. McMasters KM, Giuliano AE, Ross MI, et al: Sentinel-lymph-node biopsy for breast cancer: Not yet the standard of care. N Engl J Med 339:990-995, 1998
10. Hill AD, Mann GB, Borgen PI, et al: Sentinel lymphatic mapping in breast cancer. J Am Coll Surg 188:545-549, 1999
11. Cox CE, Pendas S, Cox JM, et al: Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg 227:645-651, 1998
12. Turner RR, Ollila DW, Krasne DL, et al: Histopathologic validation of the sentinel lymph node hypothesis for breast cancer. Ann Surg 226:271-278, 1997
13. Giuliano AE, Dale PS, Turner RR, et al: Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 222:394-399, 1995
14. Cady B: Use of primary breast carcinoma characteristics to predict lymph node metastases. Cancer 79:1856-1861, 1997
15. Silverstein MJ, Barth A: Use of primary breast carcinoma characteristics to predict lymph node metastases: Reply. Cancer 79: 1862-1864, 1997
16. Veronesi U, Paganelli G, Galimberti V, et al: Can axillary dissection be avoided in breast cancer? Lancet 349:1864-1867, 1997
17. Chadha M, Axelrod D: Is axillary dissection always indicated in invasive breast cancer? Oncology 11:1463-1468, 1997
18. Parmigiani G, Berry D, Winer EP, et al: Is axillary lymph node dissection indicated for early-stage breast cancer? A decision analysis. J Clin Oncol 17:1465-1473, 1999
19. Carter CL, Alan C, Henson DE: Relation of tumor size, lymph node status and survival in 24,740 breast cancer cases. Cancer 63:181-187, 1989
20. Nemoto T, Vana J, Bedwani RN, et al: Management and survival of female breast cancer. Cancer 45:2917-2924, 1980
21. Dees EC, Shulman LN, Souba WW, et al: Does information from axillary dissection change treatment in clinically node-negative patients with breast cancer? Ann Surg 226:279-287, 1997
22. Henderson IC, Berry D, Demetri G. et al: Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (Pts) with node-positive primary breast cancer (BC). Proc Am Soc Clin Oncol 17:101a, 1998 (abstr 390A)
23. Fisher B, Dignam J, Wolmark N, et al: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89:1673-1682, 1997
24. Ragaz J, Jackson SM, Le N, et al: Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 337:956-962, 1997
25. Overgaard M, Hansen PS, Overgaard J, et al: Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy: Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 337:949-955, 1997
26. Diab SG, Hilsenbeck SG, de Moor C, et al: Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. J Clin Oncol 16:1655-1660, 1998
27. Hill AD, Tran KN, Akhurst T, et al: Lessons learned from 500 cases of lymphatic mapping for breast cancer. Ann Surg 229:528-535, 1999
28. Barth A, Craig PH, Silverstein MJ: Predictors of axillary lymph node metastases in patients with T1 breast carcinoma. Cancer 79:1918-1922, 1997
29. Giuliano AE, Jones RC, Brennan M. et al: Sentinel lymphadenectomy in breast cancer. J Clin Oncol 15:2345-2350, 1997
30. Maibenco DC, Weiss LK, Pawlish KS, et al: Axillary lymph node metastases associated with small invasive breast carcinomas. Cancer 85:1530-1536, 1999
31. Abner AL, Collins L, Peiro G, et al: Correlation of tumor size and axillary lymph node involvement with prognosis in patients with T1 breast carcinoma. Cancer 83:2502-2508, 1998
32. Cady B, Stone MD, Schuler JG, et al: The new era in breast cancer: Invasion, size, and nodal involvement dramatically decreasing as a result of mammographic screening. Arch Surg 131:301-308, 1996